Benson Boone, Jack Black, Ariana Grande, Cynthia Erivo, Chris Evans, Selena Gomez, Jalen Hurts, Travis Kelce, Kendrick Lamar, Peyton List, Jason Momoa, MrBeast, Jenna Ortega, Keanu Reeves, Taylor Swift, Charli XCX and More, Announced as KCA NomineesShare It: @Nickelodeon @KidsChoiceAwards #KCAClick HERE to download photos and HERE to embed video.HOLLYWOOD, Calif., May 15, 2025 /PRNewswire/ -- Grammy® Award-winning, multiplatinum global superstar Tyla is set to take the Slime-tastic stage as host of the bigg ...

Core Insights - The Leukemia & Lymphoma Society (LLS) has partnered with Kroger's Dallas Division to raise funds for The Dare to Dream Project, aimed at improving treatments for pediatric blood cancer patients and providing support for their families [1][2][4] Group 1: The Dare to Dream Project - The Dare to Dream Project is a $175 million campaign focused on funding pediatric blood cancer research, advocating for healthcare policy changes, and expanding support services for affected children and families [8] - Only 5% of cancer drugs have been approved for first-time use in children, and 80% of childhood cancer survivors face chronic health issues due to their treatments [3] Group 2: Fundraising Efforts - From May 14 to June 3, 2025, Kroger encourages customers to donate at checkout in 110 stores across North and East Texas and Louisiana to support LLS's Dare to Dream Project [2] - Funds raised will exclusively benefit the life-saving work of The Dare to Dream Project, helping to ensure better treatment outcomes for children with blood cancer [1][2] Group 3: LLS's Commitment - LLS is pioneering pediatric blood cancer research, including the establishment of the first-ever pediatric AML Data Commons and the launch of the LLS PedAL Master Clinical Trial [4] - The organization has been dedicated to improving the quality of life for blood cancer patients and their families for over 75 years [6]

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) OrthoPediatrics Corp.'s unaudited Q1 2025 financial statements report a **$10.7 million** net loss, with total assets at **$470.3 million** and liabilities at **$123.1 million** [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets decreased slightly to **$470.3 million**, driven by lower cash, while total liabilities increased to **$123.1 million**, reducing stockholders' equity Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $33,439 | $43,820 | | Inventories, net | $119,752 | $117,005 | | Total current assets | $232,059 | $237,173 | | Total assets | $470,250 | $473,209 | | **Liabilities & Equity** | | | | Accounts payable - trade | $14,199 | $8,908 | | Total current liabilities | $37,505 | $33,962 | | Total liabilities | $123,104 | $118,643 | | Total stockholders' equity | $347,146 | $354,566 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net revenue for Q1 2025 increased **17.3%** to **$52.4 million**, but operating loss widened to **$11.0 million** due to increased general and administrative expenses, resulting in a **$10.7 million** net loss Condensed Consolidated Statements of Operations (in thousands, except per share data) | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net revenue | $52,411 | $44,685 | | Gross profit | $38,262 | $32,174 | | Operating loss | $(10,981) | $(9,723) | | Net loss | $(10,659) | $(7,805) | | Net loss per share (basic and diluted) | $(0.46) | $(0.34) | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$4.2 million** in Q1 2025, but overall cash, cash equivalents, and restricted cash decreased by **$10.3 million**, ending at **$35.4 million** Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(4,156) | $(6,690) | | Net cash used in investing activities | $(5,987) | $(3,679) | | Net cash used in financing activities | $(126) | $(573) | | **Net decrease in cash, cash equivalents and restricted cash** | **$(10,348)** | **$(9,463)** | | Cash, cash equivalents and restricted cash, end of period | $35,429 | $23,564 | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail accounting policies, the **Boston O&P acquisition**, a new **$100 million credit facility**, revenue growth from U.S. sales and Trauma/Deformity, and ongoing legal proceedings - On January 5, 2024, the Company acquired Boston Brace International, Inc. ("Boston O&P") for a total consideration of **$21.8 million**, consisting of **$21.5 million** in cash and **$0.2 million** in common stock[37](index=37&type=chunk)[39](index=39&type=chunk) - In August 2024, the company entered into a new credit agreement with Braidwell LP, including a **$25 million** initial term loan (with a **$25 million** delayed draw option) and issued **$50 million** in **4.75%** convertible senior notes due **2030**. This replaced the previous MidCap credit facility[53](index=53&type=chunk)[60](index=60&type=chunk)[68](index=68&type=chunk) Revenue by Geography and Category (Q1 2025 vs Q1 2024, in thousands) | Category | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **By Geography** | | | | U.S. | $40,891 | $34,305 | | International | $11,520 | $10,380 | | **By Product** | | | | Trauma and deformity | $37,867 | $33,302 | | Scoliosis | $13,664 | $10,203 | | Sports medicine/other | $880 | $1,180 | | **Total** | **$52,411** | **$44,685** | - The company is involved in a software ownership dispute with IMED Surgical, which re-initiated arbitration in September 2024. It is also a party to a wrongful death lawsuit related to its acquired Boston O&P business, for which it is indemnified by the sellers[93](index=93&type=chunk)[99](index=99&type=chunk)[101](index=101&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes **17% revenue growth** to strong product performance, while operating loss increased due to higher G&A costs, supported by **$60.8 million** in liquidity and new financing [Results of Operations](index=28&type=section&id=Results%20of%20Operations) Net revenue increased **17%** to **$52.4 million** driven by Trauma and Deformity and Scoliosis sales, while operating expenses grew **18%** due to higher sales and G&A costs Q1 2025 vs Q1 2024 Results of Operations (in thousands) | Line Item | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Net revenue | $52,411 | $44,685 | 17% | | Cost of revenue | $14,149 | $12,511 | 13% | | Sales and marketing expenses | $16,572 | $14,169 | 17% | | General and administrative expenses | $30,280 | $24,730 | 22% | | Research and development expenses | $2,351 | $2,998 | (22)% | | Net loss | $(10,659) | $(7,805) | 37% | - The **17%** revenue increase was driven by strong global performance. Trauma and deformity sales grew **14%** to **$37.9 million**, and Scoliosis sales grew **34%** to **$13.7 million**[125](index=125&type=chunk)[126](index=126&type=chunk)[127](index=127&type=chunk) - The **22%** increase in General and Administrative expenses was primarily due to additional personnel from clinic acquisitions and a **$1.0 million** increase in stock compensation[130](index=130&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, the company held **$60.8 million** in liquidity, improved operating cash flow, and secured a new **$100 million** financing arrangement to support capital needs - As of March 31, 2025, the company had cash, cash equivalents, restricted cash, and short-term investments totaling **$60.8 million**[135](index=135&type=chunk) - Net cash used in operating activities improved to **$4.2 million** for Q1 2025, compared to **$6.7 million** for Q1 2024[136](index=136&type=chunk)[137](index=137&type=chunk) - In August 2024, the company secured a **$100 million** financing arrangement with Braidwell LP, comprising a **$50 million** term loan facility and **$50 million** in convertible notes, to support its capital needs[140](index=140&type=chunk)[141](index=141&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are interest rate and foreign currency exchange rate fluctuations, with no material changes since the 2024 Annual Report - The company's greatest potential market risk exposures are interest rate risk from its indebtedness and foreign currency exchange rate risk[150](index=150&type=chunk) - No material changes in market risk have occurred since the 2024 Annual Report on Form 10-K[150](index=150&type=chunk) [Item 4. Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting during the quarter - Management concluded that as of the end of the period, disclosure controls and procedures were effective[152](index=152&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that materially affected, or are reasonably likely to materially affect, internal controls[154](index=154&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in ordinary course legal proceedings, including a software dispute and a wrongful death lawsuit, with no expected material adverse effects - The company is involved in various legal proceedings arising in the ordinary course of business, with details on specific cases referenced in Note 12 of the financial statements[156](index=156&type=chunk) [Item 1A. Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors since the 10-K, except for expanded discussion on international business risks, including potential impacts from new U.S. tariffs - The company highlights risks of doing business internationally, including changes in trade policy, tariffs, and geopolitical relations[159](index=159&type=chunk)[161](index=161&type=chunk) - Recent U.S. trade policy changes, such as a **10%** baseline reciprocal tariff on imports, could significantly increase product costs and adversely impact financial results[160](index=160&type=chunk)[162](index=162&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=34&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered equity sales and has not repurchased shares under its approved stock repurchase program - There were no unregistered sales of equity securities in the quarter[163](index=163&type=chunk) - A stock repurchase program was approved in August 2024, but no shares have been repurchased under it[166](index=166&type=chunk) [Item 3. Defaults Upon Senior Securities](index=34&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period - None[167](index=167&type=chunk) [Item 4. Mine Safety Disclosures](index=34&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Not applicable, as the company reported no mine safety disclosures - None[168](index=168&type=chunk) [Item 5. Other Information](index=34&type=section&id=Item%205.%20Other%20Information) No additional Form 8-K information was reported, and no director or officer adopted or terminated Rule 10b5-1 trading arrangements during Q1 2025 - During the three months ended March 31, 2025, no director or officer adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement[171](index=171&type=chunk) [Item 6. Exhibits](index=35&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the quarterly report, including agreements for acquisitions, debt financing, and required certifications

OrthoPediatrics (KIDS) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Philip Taylor - PrincipalDavid Bailey - President, CEO & DirectorFred Hite - CFO & COORick Wise - Managing Director - Medical Technology & SuppliesBen Haynor - Managing DirectorJoseph Conway - Equity Research Associate Conference Call Participants Matt O'Brien - AnalystRyan Zimmerman - Managing Director & Medical Technology Analyst Operator Good day and thank you for standing by. Welcome to the OrthoPediatrics Corpora ...

OrthoPediatrics (KIDS) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Philip Taylor - PrincipalDavid Bailey - President, CEO & DirectorFred Hite - CFO & COORick Wise - Managing Director - Medical Technology & SuppliesBen Haynor - Managing DirectorJoseph Conway - Equity Research Associate Conference Call Participants Matt O'Brien - AnalystRyan Zimmerman - Managing Director & Medical Technology Analyst Operator Good day and thank you for standing by. Welcome to the OrthoPediatrics Corpora ...

OrthoPediatrics (KIDS) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 Good day and thank you for standing by. Welcome to the OrthoPediatrics Corporation First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during this session, you will need to press 11 on your telephone. You will then hear automated message advising your hand is raised. To wi ...

[First Quarter 2025 and Business Highlights](index=1&type=section&id=First%20Quarter%202025%20and%20Business%20Highlights) OrthoPediatrics reported strong Q1 2025 results with 17% revenue growth, improved Adjusted EBITDA, and raised full-year guidance Q1 2025 Key Performance Indicators (in millions) | Metric | Q1 2025 | Change vs. Q1 2024 | | :--- | :--- | :--- | | Total Revenue | $52.4 | +17% | | U.S. Revenue | $40.9 | +19% | | International Revenue | $11.5 | +11% | | Trauma & Deformity Revenue | $37.9 | +14% | | Scoliosis Revenue | $13.7 | +34% | | Adjusted EBITDA | ($0.4) | Improved from ($1.1) | | Free Cash Flow Usage | N/A | Reduced by 35% YoY | - The company helped a record of nearly **39,000 children** in the first quarter of 2025[6](index=6&type=chunk) - Expanded the scoliosis portfolio with the launch of the **VerteGlide™ System** for Early Onset Scoliosis, marking the company's **80th system launch**[6](index=6&type=chunk) - CEO David Bailey highlighted **strong execution**, progress in scaling OPSB, **gaining market share**, and **successful product launches** as key drivers, confident in continued growth due to **U.S. manufacturing** and the **non-elective nature** of its procedures[4](index=4&type=chunk) [First Quarter 2025 Financial Performance](index=1&type=section&id=First%20Quarter%202025%20Financial%20Performance) Q1 2025 revenue grew 17% to $52.4 million with improved gross margin, but increased operating expenses led to a wider net loss despite improved Adjusted EBITDA [Revenue Analysis](index=1&type=section&id=Revenue%20Analysis) Revenue grew robustly across geographies and product lines, with U.S. up 19% and Scoliosis up 34%, offsetting a 25% decline in Sports Medicine/Other Q1 2025 Revenue by Geography (in millions) | Geography | Q1 2025 Revenue | Q1 2024 Revenue | Growth | | :--- | :--- | :--- | :--- | | U.S. | $40.9 | $34.3 | 19% | | International | $11.5 | $10.4 | 11% | | **Total** | **$52.4** | **$44.7** | **17%** | Q1 2025 Revenue by Product Category (in millions) | Product Category | Q1 2025 Revenue | Q1 2024 Revenue | Growth | | :--- | :--- | :--- | :--- | | Trauma and Deformity | $37.9 | $33.3 | 14% | | Scoliosis | $13.7 | $10.2 | 34% | | Sports Medicine/Other | $0.9 | $1.2 | -25% | [Profitability and Expenses](index=2&type=section&id=Profitability%20and%20Expenses) Gross profit rose 19% to $38.3 million, with margin at 73%, but increased operating expenses led to a wider net loss, though Adjusted EBITDA loss narrowed - Gross profit margin improved to **73%** in Q1 2025 from **72%** in Q1 2024, primarily due to higher domestic growth and lower international set sales[8](index=8&type=chunk) - Operating expenses increased mainly due to: - **General and administrative:** **+22%** to **$30.3M**, driven by personnel additions and increased non-cash stock compensation[9](index=9&type=chunk) - **Sales and marketing:** **+17%** to **$16.6M**, due to higher sales commissions and volume[10](index=10&type=chunk) - **Research and development:** **-22%** to **$2.4M**, due to timing of third-party invoices[11](index=11&type=chunk) Q1 2025 Profitability Metrics (in millions) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Loss | ($10.7) | ($7.8) | | Net Loss per Share | ($0.46) | ($0.34) | | Adjusted EBITDA | ($0.4) | ($1.1) | [Balance Sheet and Cash Flow](index=2&type=section&id=Balance%20Sheet%20and%20Cash%20Flow) Q1 2025 cash balance decreased to $60.8 million, but free cash flow usage improved by 35%, with positive free cash flow anticipated in Q4 2025 - Cash, cash equivalents, short-term investments, and restricted cash totaled **$60.8 million** as of March 31, 2025, down from **$70.8 million** as of December 31, 2024[14](index=14&type=chunk) - The company reduced its first quarter 2025 free cash flow usage by **35%** compared to Q1 2024 and expects to be free cash flow positive in **Q4 2025**[6](index=6&type=chunk) [Full Year 2025 Financial Guidance](index=2&type=section&id=Full%20Year%202025%20Financial%20Guidance) OrthoPediatrics raised its full-year 2025 revenue guidance to $236.0-$242.0 million (15-18% growth) and reiterated Adjusted EBITDA guidance Updated Full Year 2025 Guidance (in millions) | Metric | Previous Guidance | Updated Guidance | Implied Growth (YoY) | | :--- | :--- | :--- | :--- | | Revenue | $235.0 - $242.0 | $236.0 - $242.0 | 15% to 18% | | Adjusted EBITDA | $15.0 - $17.0 | $15.0 - $17.0 (Reiterated) | N/A | - The company reiterated its plan for annual set deployment of **$15.0 million**[15](index=15&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including Balance Sheets, Statements of Operations, Cash Flows, and revenue breakdowns [Condensed Consolidated Balance Sheets](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of March 31, 2025, total assets were $470.3 million, liabilities increased to $123.1 million, and stockholders' equity decreased to $347.1 million Key Balance Sheet Items (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, Restricted Cash & Short-term Investments | $60,762 | $70,790 | | Inventories, net | $119,752 | $117,005 | | Total Assets | $470,250 | $473,209 | | Total Liabilities | $123,104 | $118,643 | | Total Stockholders' Equity | $347,146 | $354,566 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Q1 2025 net revenue was $52.4 million, but operating loss widened to $11.0 million and net loss increased to $10.7 million, or $0.46 per share Q1 Statement of Operations Summary (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Revenue | $52,411 | $44,685 | | Gross Profit | $38,262 | $32,174 | | Total Operating Expenses | $49,243 | $41,897 | | Operating Loss | $(10,981) | $(9,723) | | Net Loss | $(10,659) | $(7,805) | | Net Loss Per Share | $(0.46) | $(0.34) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) Q1 2025 net cash used in operating activities improved to $4.2 million, while net cash used in investing activities was $6.0 million, resulting in a $10.3 million net cash decrease Q1 Cash Flow Summary (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(4,156) | $(6,690) | | Net cash used in investing activities | $(5,987) | $(3,679) | | Net cash used in financing activities | $(126) | $(573) | | **Net Decrease in Cash** | **$(10,348)** | **$(9,463)** | [Net Revenue by Geography and Product Category](index=8&type=section&id=NET%20REVENUE%20BY%20GEOGRAPHY%20AND%20PRODUCT%20CATEGORY) Q1 2025 revenue breakdown shows U.S. contributing $40.9 million (78%) and International $11.5 million (22%), with Trauma and Deformity as the largest product segment Q1 2025 vs Q1 2024 Revenue Breakdown (in thousands) | Category | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **By Geography** | | | | U.S. | $40,891 | $34,305 | | International | $11,520 | $10,380 | | **By Product** | | | | Trauma and deformity | $37,867 | $33,302 | | Scoliosis | $13,664 | $10,203 | | Sports medicine/other | $880 | $1,180 | | **Total** | **$52,411** | **$44,685** | [Non-GAAP Financial Measures Reconciliation](index=3&type=section&id=Non-GAAP%20Financial%20Measures%20Reconciliation) This section reconciles GAAP to non-GAAP measures, adjusting Q1 2025 net loss of $10.7 million to an Adjusted EBITDA loss of $0.4 million and GAAP diluted loss per share to $0.39 Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net loss (GAAP) | $(10,659) | $(7,805) | | Adjustments (Depreciation, Stock Comp, etc.) | $10,280 | $6,097 | | **Adjusted EBITDA (Non-GAAP)** | **$(379)** | **$(1,108)** | Reconciliation of Diluted Loss Per Share to Non-GAAP Adjusted Diluted Loss Per Share | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Loss per share, diluted (GAAP) | $(0.46) | $(0.34) | | Adjustments (Acquisition costs, etc.) | $0.07 | $0.04 | | **Loss per share, diluted (Non-GAAP)** | **$(0.39)** | **$(0.30)** | [Other Information](index=3&type=section&id=Other%20Information) This section provides investor logistical details, forward-looking statements disclaimer, and a corporate overview of OrthoPediatrics' exclusive focus on pediatric orthopedics - A conference call to discuss the results was scheduled for **May 7, 2025**, with a webcast available for replay on the company's investor relations website[16](index=16&type=chunk) - The company identifies itself as being exclusively focused on pediatric orthopedics, marketing **80 systems** across trauma and deformity, scoliosis, and sports medicine in the U.S. and over **75 other countries**[20](index=20&type=chunk) - The press release contains forward-looking statements that involve risks and uncertainties, and the company directs investors to its SEC filings for a full list of risk factors[17](index=17&type=chunk)

First Quarter 2025 Revenue Increased 17% Year-over-YearWARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Business Highlights Helped a record of nearly 39,000 children in the first quarter of 2025Generated total revenue of $52.4 million for the first quarte ...

Core Insights - OrthoPediatrics Corp. has announced the expansion of its Trauma and Deformity portfolio with the introduction of the 3P Pediatric Plating Platform Hip System, marking its fifth FDA approval in 2025 [1][3]. Product Development - The 3P Pediatric Plating Platform Hip System is designed to modernize trauma and deformity correction treatments in lower extremities, providing surgeons with enhanced coverage for various indications through unique implants and instruments [2]. - The beta launch of the 3P Hip is expected to be followed by the 3P Small/Mini system in early 2026, with additional systems planned for future launches, aiming to transform the company's plate and screw product portfolio [2]. Company Strategy - The Trauma and Deformity division President highlighted the 3P Pediatric Plating Platform as a significant opportunity to address unmet needs in the market, representing one of the largest product initiatives in the company's history [3]. - The CEO emphasized the commitment to providing a comprehensive portfolio of innovative orthopedic treatments for pediatric patients, reflecting the company's focus on expanding its product offerings [3]. Company Overview - Founded in 2006, OrthoPediatrics specializes in pediatric orthopedics, offering over 80 products across major categories including trauma and deformity, scoliosis, and sports medicine [4]. - The company distributes its products in the United States and over 70 countries globally, focusing exclusively on pediatric orthopedic solutions [4].

Company Overview - OrthoPediatrics Corp. is focused exclusively on advancing pediatric orthopedics, having developed a comprehensive product offering to improve the lives of children with orthopedic conditions [3] - The company markets over 80 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [3] - OrthoPediatrics has a global sales organization that distributes its products in the United States and over 70 countries outside the United States [3] Upcoming Financial Results - OrthoPediatrics is scheduled to release its first quarter 2025 financial results on May 7, 2025, after the market closes [1] - A conference call will be held on the same day at 4:30 p.m. ET to discuss the financial results [1] Investor Information - Investors can access a live and archived webcast of the conference call on the company's website, which will be available for replay for at least 90 days after the event [2]